Your cart is ready — click here to view your products.

Tirz (GLP-1 / GIP) (5mg / 10mg)-5mg

  • purity_percentage Icon 99% Purity
$129
Description
 

Tirz (GLP-1)
Dual Incretin Peptide for Metabolic, Endocrine, and Obesity Research

Tirz is a synthetic dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This novel peptide is of great interest in metabolic and endocrine research, particularly in models involving glucose regulation, energy balance, and weight management pathways.

Product Overview
Supplied in lyophilized format, Tirz is available for in vitro and preclinical exploration in models evaluating insulin sensitivity, adipocyte function, and incretin hormone signaling.

Key Research Attributes:

  • GLP-1 and GIP Dual Activity: Mimics endogenous incretins to enhance glucose-stimulated insulin secretion and satiety signaling.
  • Insulin Sensitivity: Explored in studies assessing improved glucose uptake and pancreatic beta-cell preservation.
  • Body Weight Modulation: Utilized in obesity-related research targeting reduced energy intake and enhanced metabolic expenditure.
  • Chronic Disease Models: Investigated in laboratory models of metabolic syndrome, type 2 diabetes, and lipid metabolism disorders.


Applications in Scientific Research

  • Incretin pathway and peptide hormone signaling studies
  • Glucose homeostasis and insulin secretion models
  • Obesity and energy regulation research
  • Liver lipid metabolism and hepatic steatosis studies
  • Endocrinology-focused preclinical experiments

Format and Storage
Form: Lyophilized powder
Purity: >99%
Storage: Store at -20°C in a dry, dark location
Reconstitution: Reconstitute with sterile bacteriostatic water under aseptic conditions

Disclaimer: Tirz (GLP-1) is provided exclusively for laboratory-based, in vitro scientific research. It is not intended for human or veterinary use. All handling must comply with institutional and legal safety requirements.



Chemical Makeup

Molecular Formula

  • Tirz: C225H348N48O68

Molecular Weight

  • Tirz: 4813.5 g/mol

Other Known Titles

  • Tirz: LY3298176, Dual GIP/GLP-1 Receptor Agonist
 

Tirz (GLP-1) is intended for qualified scientific research use only. All purchases are subject to our Terms and Conditions.

More Information
Purity Percentage 99% Purity
Volume 5MG
Bought This Week 10
New No
Sale Yes
Research

Tirz Research: Effects, Benefits, and Side Effects

  • Tirz: A Comprehensive Review of its Clinical Efficacy, Safety, and Future Implications
    This article provides an in-depth review of Tirz, covering its mechanism of action, benefits for weight management and glycemic control, and safety profile. Read more
  • Tirz Slows Progression of Kidney Disease in Type 2 Diabetes
    Study shows Tirz may reduce progression of chronic kidney disease in patients with type 2 diabetes. Read more
  • Adverse Effects with Tirz: Meta-Analysis Protocol
    BMJ Open protocol outlining an upcoming systematic review on the side effect profile of Tirz. Read more
  • Metabolic Benefits of Tirz: A Narrative Review
    Examines cardiovascular and neuroprotective potential beyond diabetes and weight loss. Read more
  • Tirz Shown to Improve Heart Health & Reduce Weight
    Studies highlight dual benefits of fat loss and cardiovascular support, with side effect considerations. Read more
  • Three-Year Weight Loss Results from Tirz
    Clinical data showing long-term weight reduction from Tirz therapy. Read more
  • Neuroprotective Effects of Tirz
    Research on how Tirz may reduce cognitive decline and support brain health. Read more
  • Tirz Overview: How it Works, Side Effects, and Cost
    Full guide to dosing, injection, mechanism of action, and safety. Read more
  • Tirz Lowers Risk of Death in Type 2 Diabetes
    Clinical trials show reduced mortality risk in diabetic patients taking Tirz. Read more